104 related articles for article (PubMed ID: 11306964)
1. T cytotoxic 1 and T cytotoxic 2 CD8 T cells both inhibit IgE responses.
Thomas MJ; MacAry PA; Noble A; Askenase PW; Kemeny DM
Int Arch Allergy Immunol; 2001; 124(1-3):187-9. PubMed ID: 11306964
[TBL] [Abstract][Full Text] [Related]
2. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation.
Thomas MJ; Noble A; Sawicka E; Askenase PW; Kemeny DM
J Immunol; 2002 Jan; 168(1):216-23. PubMed ID: 11751965
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
6. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
7. Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE.
MacAry PA; Holmes BJ; Kemeny DM
J Immunol; 1998 Jan; 160(2):580-7. PubMed ID: 9551891
[TBL] [Abstract][Full Text] [Related]
8. An essential role for IL-18 in CD8 T cell-mediated suppression of IgE responses.
Salagianni M; Wong KL; Thomas MJ; Noble A; Kemeny DM
J Immunol; 2007 Apr; 178(8):4771-8. PubMed ID: 17404257
[TBL] [Abstract][Full Text] [Related]
9. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells.
Holmes BJ; MacAry PA; Noble A; Kemeny DM
Eur J Immunol; 1997 Oct; 27(10):2657-65. PubMed ID: 9368623
[TBL] [Abstract][Full Text] [Related]
11. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
12. Tc2 cells respond to soluble antigen in the respiratory tract and induce lung eosinophilia and bronchial hyperresponsiveness.
Sawicka E; Noble A; Walker C; Kemeny DM
Eur J Immunol; 2004 Sep; 34(9):2599-608. PubMed ID: 15307192
[TBL] [Abstract][Full Text] [Related]
13. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J
Immunology; 2007 Feb; 120(2):148-59. PubMed ID: 17274112
[TBL] [Abstract][Full Text] [Related]
14. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
15. CD8+ tumor-specific Tc cells primed in vivo or in vitro against the BALB/c plasmacytoma ADJ-PC-5 use the same TcR V beta families but display distinct TC1 or TC2 characteristics.
Becker C; Kölsch E; Pauels HG
Immunobiology; 1997 Jun; 197(1):16-30. PubMed ID: 9241528
[TBL] [Abstract][Full Text] [Related]
16. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
[TBL] [Abstract][Full Text] [Related]
18. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Th2 responses and allergic inflammation through bystander activation of CD8+ T lymphocytes in early life.
Dubois A; Deruytter N; Adams B; Kanda A; Delbauve S; Fleury S; Torres D; François A; Pétein M; Goldman M; Dombrowicz D; Flamand V
J Immunol; 2010 Jul; 185(2):884-91. PubMed ID: 20562264
[TBL] [Abstract][Full Text] [Related]
20. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
